FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This study is a single-center exploratory clinical trial. It is estimated that 6-12 subjects
will be enrolled. The "BOIN" dose escalation design is adopted. The main purpose is to
evaluate the safety of FKC288 in the treatment of subjects with relapsed or refractory AL
amyloidosis and explore the recommended phase II dose of FKC288 in the treatment of patients
with relapsed/refractory systemic Light Chain (AL) amyloidosis.